Lonafarnib-Based Regimens Look Promising for Patients With Chronic HDV Infection
The all-oral and combination treatment arms demonstrated statistically significant composite responses of 10.1% and 19.2%, respectively.
Diagnosis & Disease Information
Vemlidy Approved for Pediatric Patients With Chronic HBV Infection
The approval was supported by data from a phase 2 trial that included 70 patients aged 12 to less than 18 years with chronic HBV infection.
Hepatitis C Transmission Risk From Syringes With Fixed vs Detachable Needles
Investigators conducted a study to determine the effect of syringes with fixed needles vs those with detachable needles on the risk for hepatitis C virus transmission among people who use injectable drugs.
ACIP: 2022 Adult Immunization Schedule Updates
The 2022 adult immunization schedule summarizes ACIP recommendations, including several changes.
Zepatier Approval Expanded to Include HCV Treatment of Pediatric Patients
The approval was based on data from a phase 2b study which evaluated Zepatier in 22 patients aged 12 to less than 18 years.
Bulevirtide BLA Submitted for Chronic Hepatitis Delta Virus Infection
The application submission is supported by data from the ongoing phase 3 MYR301 study, along with completed and ongoing phase 2 studies.
Drug-Induced Hepatotoxicity Ends Development of Novel HBV Therapy
The phase 2 trial was evaluating the effects of ABI-H2158 in 88 treatment-naïve patients with HBeAg positive or HBeAg negative chronic hepatitis B infection without cirrhosis.
New Vial Sizes for Bivigam, Nabi-HB Now Available
The new vial sizes are currently in stock and commercially available in the US.
Epclusa Approved for Younger Patients With Chronic Hepatitis C
The expanded approval was based on data from an open-label phase 2 trial that evaluated Epclusa in 41 patients 3 years to less than 6 years of age with chronic HCV infection.
New Formulation of Hepatitis B Immune Globulin Launches
HyperHEP B is the Grifol’s new formulation of its hepatitis B immune globulin.
- Loading...
Loading...
Next post in News
Loading... 
Loading...